Navigation Links
Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Date:11/1/2007

Factor IXa, a protein that is critical to blood coagulation. The antidote component, RB007, is a complementary nucleic acid that binds to and neutralizes RB006. The binding of RB007 to RB006 causes the predictable and rapid reversal of RB006 that allows the patient's blood to return to normal.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of drug:antidote systems. Regado's drug:antidote systems are designed to give physicians the ability to fine-tune the therapeutic effect desired for each patient and in each setting. A spin-out of the Department of Surgery at Duke University Medical Center, Regado was created to answer the therapeutic needs identified by its scientific founders.

The Company's proprietary platform technology enables the discovery of oligonucleotide-based drug-antidote pairs to any target protein. Regado initially is focusing its discovery and development efforts on the acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles. Potential future indications for Regado's technology include acute coronary syndromes and other coronary revascularization procedures that would benefit from the availability of an antidote-reversible agent.


'/>"/>
SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
(Date:9/17/2014)... OTEMR, Inc. , ONETOUCH EMR, 2.0 has achieved ONC ... the software is capable of supporting eligible providers with ... measures required to qualify for funding under the American ... certified on July 14, 2014 by ICSA Labs ... (ONC-ACB) and is compliant in accordance with applicable criteria ...
(Date:9/17/2014)... Sept. 17, 2014  Members of the physician ... Associates announced today that the enterprise is ... its image sharing capabilities and provide immediate cluster ... failures. In addition, the Dicom Systems enterprise imaging ... PACS systems to more effectively deliver the right ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... 4 NovaRx Corporation announced today the appointment of ... and Chief Operating Officer. Dr. Russell brings to ... discovery and a long history of success driving innovation ... experience leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... - Tasigna front-line data demonstrating potential in newly diagnosed patients with ... sessions at ASH , , - ... by significantly reducing toxic iron that can damage key organs , ... major independent breast cancer trial at SABCS to report on optimal ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
(Date:9/17/2014)... Final Cut Pro X plugin developers have announced a new ... , “ProBlue 5k is a compilation of anamorphic flares that ... Christina Austin, CEO of Pixel Film Studios. “Blurring the line ... changer.” , ProBlue 5k is the ultimate Ultra High Definition ... footage compilation of over 100 anamorphic flares can be applied ...
(Date:9/17/2014)... Las Vegas, NV (PRWEB) September 17, 2014 ... by Dr. Dan Ritchie and Dr. Cody Sipe that is ... quality of life and longevity has caught the attention of ... ask most people in their 50s, 60s, or even 70s ... quality of life on a day-to-day basis, they would probably ...
(Date:9/17/2014)... the ends of chromosomes could hold the key to a ... skin cancer according to new research from the University ... new genetic risk factor for melanoma. , It is well ... of those most at risk of developing melanoma. For example, ... they burn more easily. , It now appears that another ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of Discovery ... would be beneficial in this [MDL].” Accordingly, the court ... end of December,” the order further provides, “the court ... , “The plain import of this order is ... to be discussed as these cases progress toward trial,” ...
(Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2
... SAGE Launch Clinical Psychological Science ,Association for Psychological ... Angeles, CA (April 23, 2012) The Association for ... Clinical Psychological Science , a new peer-reviewed journal focused ... venue for cutting-edge research across a wide range of ...
... Guy, M.D., professor of ophthalmology at Bascom Palmer Eye ... Medicine, has pioneered a novel technological treatment for Leber ... causes rapid, permanent, and bilateral loss of vision in ... Genetic mutations in the mitochondria (part of the ...
... 23 (HealthDay News) -- Teen drivers and passengers are more likely ... belt laws, often promoted as "click it or ticket" laws, a ... and ticket drivers solely for not wearing a seat belt. Under ... are stopped for other reasons, such as speeding. Primary seat ...
... The Global Cardiovascular Disease Taskforce called on the 11,000 ... cardiovascular disease (CVD) community at large, to support the ... disease (NCD) mortality by 25 per cent by 2025. ... from the world,s largest CVD organizations including the American ...
... Hispanic lung cancer patients seem to live longer than ... Cancer , a peer-reviewed journal of the American Cancer ... types of cancer, certain yet-to-be-defined genetic and/or environmental factors ... studies that look at ethnic and racial disparities in ...
... Health (NIH) scientists and their colleagues in China have ... called sasX , which plays a pivotal role ... in most of Asia. Senior author Michael Otto, Ph.D., ... says these findings illustrate at the molecular level how ...
Cached Medicine News:Health News:Association for Psychological Science, SAGE launch Clinical Psychological Science 2Health News:Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder 2Health News:Stricter Seat Belt Laws Get Teens to Buckle Up, Study Shows 2Health News:Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology 2Health News:Hispanic lung cancer patients tend to live longer than blacks and whites 2Health News:NIH scientists link quickly spreading gene to Asian MRSA epidemic 2
Tracheal Suction Latex Rubber Catheters - Funnel End...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning....
... The Paradigm LD400 FT is an affordable ... exam time by at least 40%. It has ... It features rapid setup and easy two-button operation ... friendly. The LD 400 FT is the workhorse ...
Medicine Products: